Isarna Therapeutics GmbH

https://www.isarna-therapeutics.com

Isarna Therapeutics was built on profound knowledge in antisense oligonucleotide design and therapeutic development of this innovative compound class. Today, Isarna is developing a portfolio of antisense therapies targeting an emerging therapeutic field in human biology: TGF-ß signaling. Precise modulation of TGF-ß pathways using antisense therapy may result in safer and more effective treatment options for a broad range of indications. Currently, Isarna is focused on ophthalmology; its lead compound, ISTH0036, will soon enter Phase 2a clinical development in the blockbuster indications AMD and DME. In addition, Isarna has established a portfolio of antisense compounds addressing three important isoforms of TGF-ß to treat fibrotic liver disease, such as NASH, and various forms of cancer. *

	Start	2013-09-30 renamed
	Predecessor	Antisense Pharma GmbH
	Industry	antisense drug
	Industry 2	cancer drug
	Person	Schalper, Claus (Isarna Therapeutics 202109– CEO before XL-protein+ Pieris)

	Region	München (Munich)
	Country	Germany
	Street	109a Schellingstr.
	City	80798 München
	Tel	+49-89-890831-0
		Address record changed: 2021-10-25

Basic data	Employees	C: 51 to 100 (2008-10-01)

		* Document for »About Section«:

		Record changed: 2023-12-30

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Isarna Therapeutics GmbH

[1] Isarna Therapeutics GmbH. (9/30/21). "Press Release: Isarna Therapeutics Appoints Claus Schalper as CEO". Munich....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)